Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FEX60/PE10 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| FEX60/PE10 | EXPERIMENTAL | Internal use of FEX60/PE10 combination tablet will be administered twice daily (1 tablet per intake) for 2 weeks |
| Name | Type | Description |
|---|---|---|
| FEX60/PE10 | DRUG | Pharmaceutical form:tablet Route of administration: oral |
Inclusion criteria: * Outpatients with a history of seasonal or perennial allergic rhinitis for at least 1 year confirmed by positive skin prick test to out or indoor allergens (wheal ≥3mm compared to control \[diluent\]) or positive specific IgE Antibody test (ie, radioallergosorbent test \[RAST\]...
FEX60/PE10 is an investigational fixed combination tablet being studied for the treatment of allergic rhinitis. It is a small molecule developed by Sanofi. The drug is currently in Phase 3 clinical development, though the specific trial evaluating it has been completed.
FEX60/PE10 is developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker SNY. The drug is being investigated as a treatment for allergic rhinitis and is currently in Phase 3 clinical development.
FEX60/PE10 is in Phase 3 clinical development. The drug is being studied for allergic rhinitis, and the Phase 3 trial has been completed. FEX60/PE10 remains investigational and has not been approved by regulatory authorities.
FEX60/PE10 has been evaluated in a Phase 3 clinical trial registered as NCT02401191. This study assessed the safety and effectiveness of the FEX60/PE10 fixed combination tablet in patients with allergic rhinitis. The trial enrolled 105 participants in Japan and has been completed.